3 results
Primary Objective1. The main objective of this study is to demonstrate that OM/AML/HCTZ triple combinations are more efficacious in lowering SeDBP than corresponding dual combinations of OM/AML after 10 weeks of double blind treatment.Secondary…
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
To demonstrate the safety, performance and effectiveness of the EMPOWER* Modular Pacing System (MPS), as well as the EMPOWER and EMBLEM* Subcutaneous ICD Coordinated System. Additionally, data from this study may be used to support pre-market and…